Business Description
Biofrontera Inc
NAICS : 325411
SIC : 2834
ISIN : US09077D2099
Total Employee Number:
94Description
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.82 | |||||
Equity-to-Asset | 0.25 | |||||
Debt-to-Equity | 1.27 | |||||
Debt-to-EBITDA | -0.82 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -6.63 | |||||
Beneish M-Score | 0.65 | |||||
WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -46.7 | |||||
3-Year EPS without NRI Growth Rate | 59.7 | |||||
3-Year FCF Growth Rate | 55.9 | |||||
3-Year Book Growth Rate | -63.1 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 15.01 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.2 | |||||
Quick Ratio | 1.09 | |||||
Cash Ratio | 0.58 | |||||
Days Inventory | 130.5 | |||||
Days Sales Outstanding | 37.43 | |||||
Days Payable | 124.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -105.9 | |||||
Shareholder Yield % | -22.16 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 77.29 | |||||
Operating Margin % | -24.83 | |||||
Net Margin % | -25.66 | |||||
EBITDA Margin % | -21.78 | |||||
FCF Margin % | -21.53 | |||||
OCF Margin % | -21.52 | |||||
ROE % | -567.3 | |||||
ROA % | -52.54 | |||||
ROIC % | -96.1 | |||||
3-Year ROIIC % | -245.56 | |||||
ROC (Joel Greenblatt) % | -369.46 | |||||
ROCE % | -129.75 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Forward PE Ratio | 620 | |||||
PS Ratio | 0.26 | |||||
PB Ratio | 2 | |||||
Price-to-Tangible-Book | 3.52 | |||||
EV-to-EBIT | -1.41 | |||||
EV-to-EBITDA | -1.54 | |||||
EV-to-Revenue | 0.33 | |||||
EV-to-Forward-Revenue | 0.08 | |||||
EV-to-FCF | -1.55 | |||||
Price-to-GF-Value | 1.89 | |||||
Earnings Yield (Greenblatt) % | -70.92 | |||||
FCF Yield % | -71.35 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Biofrontera Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 37.109 | ||
| EPS (TTM) (€) | -0.964 | ||
| Beta | -0.1648 | ||
| 3-Year Sharpe Ratio | -0.71 | ||
| 3-Year Sortino Ratio | -0.75 | ||
| Volatility % | - | ||
| 14-Day RSI | - | ||
| 14-Day ATR (€) | - | ||
| 20-Day SMA (€) | 8.06 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range (€) | 8.06 - 8.06 | ||
| Shares Outstanding (Mil) | 12.8 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Biofrontera Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Biofrontera Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 10:00 | In 136 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 135 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-14 10:00 | In 45 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 43 days | ||
| General meeting for 2025 | 2026-06-11 10:00 | 8.06 (+0.00%) | ||
| Guidance call for 2026 | 2026-05-28 11:00 | 8.06 (+0.00%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 11:00 | 8.06 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 8.06 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-19 10:00 | 8.06 (+0.00%) | ||
| Annual report for 2025 | 2026-03-19 | 8.06 (+0.00%) |
Show
Entries
Biofrontera Inc Frequently Asked Questions
What is Biofrontera Inc(STU:AI10)'s stock price today?
The current price of STU:AI10 is €8.06. The 52 week high of STU:AI10 is €8.06 and 52 week low is €8.06.
When is next earnings date of Biofrontera Inc(STU:AI10)?
The next earnings date of Biofrontera Inc(STU:AI10) is 2026-08-13 Est..
Does Biofrontera Inc(STU:AI10) pay dividends? If so, how much?
Biofrontera Inc(STU:AI10) does not pay dividend.
Press Release
Articles on Biofrontera Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers